Bibliographic Details
| Title: |
Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection |
| Authors: |
Deniz GÖKENGİN, Oğuzhan ACET |
| Source: |
Mediterranean Journal of Infection, Microbes and Antimicrobials, Vol 11, Iss 1 (2022) |
| Publisher Information: |
Galenos Yayinevi, 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Medicine
LCC:Infectious and parasitic diseases |
| Subject Terms: |
dolutegravir, lamivudine, dual antiretroviral treatment, Medicine, Infectious and parasitic diseases, RC109-216 |
| More Details: |
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virologic suppression could be achieved or maintained in patients with baseline or acquired M184V/I mutation, doubts exists about its use. This report presents a patient living with human immunodeficiency virus infection who had no resistance test results available, had heavy treatment experience, and maintained viral suppression following switching to DTG + 3TC dual therapy. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
Turkish |
| ISSN: |
2147-673X |
| Relation: |
https://www.mjima.org/text.php?&id=356; https://doaj.org/toc/2147-673X |
| DOI: |
10.4274/mjima.galenos.2022.2022.46 |
| Access URL: |
https://doaj.org/article/e55b1c4eb5d64aeeb5083661565ff342 |
| Accession Number: |
edsdoj.55b1c4eb5d64aeeb5083661565ff342 |
| Database: |
Directory of Open Access Journals |
